Acutaas Chemicals Ltd vs Senores Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Acutaas Chemicals Ltd is ₹ 2596 as of 30 Apr 15:30 . The P/E Ratio of Acutaas Chemicals Ltd changed from 50.6 on March 2022 to 125.9 on March 2025 . This represents a CAGR of 25.59% over 4 yearsThe P/E Ratio of Senores Pharmaceuticals Ltd changed from 45 on March 2025 to 45 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of Acutaas Chemicals Ltd changed from ₹ 3642 crore on March 2022 to ₹ 9994 crore on March 2025 . This represents a CAGR of 28.70% over 4 yearsThe Market Cap of Senores Pharmaceuticals Ltd changed from ₹ 2637 crore on March 2025 to ₹ 2637 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Acutaas Chemicals Ltd for the Mar '26 is ₹ 443.86 crore as compare to the Dec '25 revenue of ₹ 397.88 crore. This represent the growth of 11.56% The revenue of Senores Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 178.34 crore. This represent the decline of -100% The ebitda of Acutaas Chemicals Ltd for the Mar '26 is ₹ 194.62 crore as compare to the Dec '25 ebitda of ₹ 155.35 crore. This represent the growth of 25.28% The ebitda of Senores Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 57.79 crore. This represent the decline of -100% The net profit of Acutaas Chemicals Ltd changed from ₹ 14.69 crore to ₹ 134.28 crore over 8 quarters. This represents a CAGR of 202.34% The net profit of Senores Pharmaceuticals Ltd changed from ₹ 10.91 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Acutaas Chemicals Ltd changed from 15.19 % on March 2022 to 7.7 % on March 2025 . This represents a CAGR of -15.62% over 4 yearsThe Dividend Payout of Senores Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Acutaas Chemicals Ltd

Acutaas Chemicals Limited was initially formed as partnership firm in the name of 'Ami Organics' on 3 January, 2004 at Surat, India.
The Firm converted into a Private Limited Company under the name of 'Ami Organics Private Limited' with a Certificate of Incorporation dated 12 June, 2007.
Subsequently, the Company was converted into a Public Limited Company, reflecting the change in name of the Company to 'Ami Organics Limited' on April 18, 2018.
The name of the Company has now changed to Acutaas Chemicals Limited with effect from May 15, 2025, pursuant to the receipt of Fresh Certificate of Incorporation from the Registrar of Companies. The Company is engaged in business of drugs intermediate chemicals and related activities.
The Company is one of the major manufacturers of Pharma Intermediates for certain key APIs, including Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban.

About Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Limited was originally incorporated as 'Senores Pharmaceuticals Private Limited' through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.
Thereafter, the name of the Company was changed to 'Senores Pharmaceuticals Limited' upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms.
The Regulated Markets business is focused on Regulated Markets of US and Canada.
The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs.

FAQs for the comparison of Acutaas Chemicals Ltd and Senores Pharmaceuticals Ltd

Which company has a larger market capitalization, Acutaas Chemicals Ltd or Senores Pharmaceuticals Ltd?

Market cap of Acutaas Chemicals Ltd is 21,258 Cr while Market cap of Senores Pharmaceuticals Ltd is 4,138 Cr

What are the key factors driving the stock performance of Acutaas Chemicals Ltd and Senores Pharmaceuticals Ltd?

The stock performance of Acutaas Chemicals Ltd and Senores Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Acutaas Chemicals Ltd and Senores Pharmaceuticals Ltd?

As of May 4, 2026, the Acutaas Chemicals Ltd stock price is INR ₹2596.55. On the other hand, Senores Pharmaceuticals Ltd stock price is INR ₹898.7.

How do dividend payouts of Acutaas Chemicals Ltd and Senores Pharmaceuticals Ltd compare?

To compare the dividend payouts of Acutaas Chemicals Ltd and Senores Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.